Maple Research overview of tirzepatide, a dual GIP/GLP-1 receptor agonist engineered from the GIP peptide sequence. Covers receptor pharmacology, biased agonism, metabolic mechanisms, and clinical trial program. All information sourced from peer-reviewed literature.
Molecular Profile
| Generic Name | Tirzepatide |
|---|---|
| Brand Name(s) | Mounjaro (diabetes), Zepbound (obesity) |
| Peptide Length | 39 amino acids |
| Molecular Weight | ~4,813.45 g/mol |
| CAS Number | 2023788-19-2 |
| Classification | Dual GIP/GLP-1 receptor agonist (twincretin) |
| Structure Basis | Engineered from native GIP(1-42) sequence |
| Modification | C20 fatty diacid moiety via Lys20 for albumin binding and extended half-life |
| Half-Life | ~5 days (enables once-weekly dosing) |
| Regulatory Status | FDA approved 2022 (T2DM), 2023 (obesity) |
Receptor Pharmacology: Imbalanced Dual Agonism
Tirzepatide’s mechanism is more nuanced than simple dual agonism. Willard et al. (2020) established that tirzepatide is an “imbalanced and biased” dual agonist. At clinically relevant doses, tirzepatide engages the GIP receptor with substantially greater occupancy than the GLP-1 receptor, creating an imbalance favoring GIP receptor activation (DOI: 10.1172/jci.insight.140532).
GIP Receptor: Full, Balanced Agonism
At the GIP receptor, tirzepatide mimics native GIP across all measured signaling pathways (cAMP production, beta-arrestin recruitment, receptor internalization). This full agonism, combined with higher receptor occupancy, means GIP receptor signaling is the dominant pharmacological action at therapeutic doses.
GLP-1 Receptor: Biased Agonism
At the GLP-1 receptor, tirzepatide exhibits signaling bias: it effectively generates cAMP (the primary signaling cascade for insulin secretion) but shows reduced beta-arrestin recruitment and receptor internalization compared to native GLP-1. Willard et al. demonstrated that beta-arrestin1 limits the insulin response to GLP-1, but not to GIP or tirzepatide. This biased agonism may explain why tirzepatide’s GLP-1 receptor engagement, despite being lower in occupancy, still produces robust metabolic effects with potentially improved tolerability.
Metabolic Mechanisms
Beta-Cell Function and Insulin Sensitivity
Thomas et al. (2021) demonstrated that tirzepatide improves both beta-cell function (increased HOMA2-B) and insulin sensitivity (decreased HOMA2-IR, increased adiponectin, IGFBP-1, IGFBP-2) to a greater extent than the selective GLP-1 receptor agonist dulaglutide. Critically, the insulin sensitivity improvements were only partly attributable to weight loss (13-21% explained by weight reduction), suggesting dual receptor agonism confers distinct metabolic mechanisms beyond caloric deficit (DOI: 10.1210/clinem/dgaa863).
GIP and Adipose Tissue Biology
Samms, Coghlan, & Sloop (2020) reviewed the complexity of GIP receptor signaling in adipose tissue. While GIP was historically considered lipogenic, the review presents evidence that GIP improves lipid and glucose metabolism when paired with GLP-1’s anorexigenic mechanism. The GIP receptor is expressed in adipose tissue, and GIP signaling may promote adipose tissue remodeling, lipid buffering capacity, and adipokine secretion patterns that complement GLP-1’s central appetite suppression (DOI: 10.1016/j.tem.2020.02.006).
Clinical Trial Program (SURPASS)
Nauck & D’Alessio (2022) provided a comprehensive review of the SURPASS clinical program. Across five phase 3 trials in type 2 diabetes (SURPASS 1-5), tirzepatide at 5-15 mg weekly demonstrated HbA1c reductions of 1.24-2.58% and body weight reductions of 5.4-11.7 kg. Between 23-62% of subjects achieved normoglycemia (HbA1c <5.7%), and 20.7-68.4% lost more than 10% of baseline body weight (DOI: 10.1186/s12933-022-01604-7).
Comparison: Incretin-Based Compounds
| Parameter | Tirzepatide | Semaglutide | Retatrutide |
|---|---|---|---|
| Receptor Targets | GIP + GLP-1 (dual) | GLP-1 only (selective) | GIP + GLP-1 + Glucagon (triple) |
| Structural Basis | GIP sequence | GLP-1 analogue | GIP sequence |
| Half-Life | ~5 days | ~7 days | ~6 days |
| GLP-1R Signaling | Biased (cAMP > beta-arrestin) | Balanced | Biased |
| Max Weight Loss (Phase 3) | ~22.5% (obesity trial) | ~15-17% | ~24% (Phase 2) |
| Regulatory Status | FDA approved (2022/2023) | FDA approved (2017/2021) | Phase 3 trials |
| Unique Feature | GIP-dominant pharmacology | Longest clinical track record | Glucagon-mediated energy expenditure |
Body Composition Considerations
Locatelli et al. (2024) highlighted that incretin-based therapies, including tirzepatide, cause significant lean mass loss (~10% or ~6 kg) alongside fat loss, comparable to a decade or more of aging-related muscle loss. The review proposed that resistance exercise training should be investigated as an adjunct to incretin therapy to optimize body composition outcomes (DOI: 10.2337/dci23-0100).
Research Product Specifications
Maple Research Labs – Tirzepatide 10MG
Purity verified via third-party HPLC and mass spectrometry
Lyophilized, research-grade
Key Research Citations
| Citation | Focus | DOI |
|---|---|---|
| Willard et al., 2020 | Imbalanced and biased dual GIP/GLP-1 agonism | 10.1172/jci.insight.140532 |
| Samms, Coghlan & Sloop, 2020 | GIP enhancement of GLP-1 therapeutic efficacy | 10.1016/j.tem.2020.02.006 |
| Thomas et al., 2021 | Beta-cell function and insulin sensitivity improvements | 10.1210/clinem/dgaa863 |
| Nauck & D’Alessio, 2022 | SURPASS program comprehensive review | 10.1186/s12933-022-01604-7 |
| Locatelli et al., 2024 | Lean mass loss and resistance exercise adjunct | 10.2337/dci23-0100 |
Related Research Pages
GLP-1 & Incretin Pathway Overview | Broader context on incretin biology and compound landscape
Purity Testing Methods | How HPLC and mass spectrometry verify peptide identity
Frequently Asked Questions
What is tirzepatide and how does it differ from GLP-1 agonists?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both incretin hormone receptors simultaneously. Unlike selective GLP-1 receptor agonists (such as semaglutide or liraglutide), tirzepatide is engineered from the GIP peptide sequence and engages the GIP receptor with greater occupancy than the GLP-1 receptor at clinical doses. It also exhibits biased agonism at the GLP-1 receptor, favoring cAMP signaling over beta-arrestin recruitment. This dual mechanism has produced greater metabolic improvements than selective GLP-1 agonism in head-to-head clinical comparisons.
What does “biased agonism” mean in tirzepatide research?
Biased agonism refers to a ligand that preferentially activates certain downstream signaling pathways over others at the same receptor. At the GLP-1 receptor, tirzepatide preferentially stimulates cAMP production (which drives insulin secretion) while showing reduced beta-arrestin recruitment and receptor internalization compared to native GLP-1. Since beta-arrestin1 has been shown to limit the insulin response to GLP-1, this bias may allow tirzepatide to achieve stronger metabolic effects per unit of GLP-1 receptor engagement.
Where can I buy tirzepatide for research in Canada?
Maple Research Labs supplies tirzepatide as a research-grade reagent within Canada, with third-party purity verification via HPLC and mass spectrometry. All products include batch-specific Certificates of Analysis and ship same-day from Canadian facilities. Tirzepatide is supplied exclusively for in-vitro and preclinical research, not for human consumption or therapeutic use.
How does tirzepatide compare to retatrutide in research?
Tirzepatide is a dual agonist (GIP + GLP-1), while retatrutide is a triple agonist (GIP + GLP-1 + glucagon receptor). The addition of glucagon receptor agonism in retatrutide may increase energy expenditure through hepatic and thermogenic pathways. Phase 2 data for retatrutide showed up to 24% weight reduction, compared to 22.5% for tirzepatide in obesity trials, though retatrutide has not yet completed phase 3 trials. Both compounds are engineered from the GIP peptide backbone and share the biased GLP-1 receptor signaling profile.